U.S.-South Africa Program for Collaborative Biomedical Research Phase 3 (HIV/AIDS) (R01 Clinical Trial Optional)
ID: 356439Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $400K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356439

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-023.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced the U.S.-South Africa Program for Collaborative Biomedical Research Phase 3, focusing on HIV/AIDS and related health issues. This funding opportunity aims to foster collaborative research projects between U.S. and South African investigators, emphasizing the development of partnerships that enhance scientific discovery and public health outcomes. With approximately $3.8 million available to support 8-10 awards, eligible applicants must include at least one principal investigator from a recognized South African institution collaborating with a U.S. entity, and applications are due by March 12, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-023.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-24-023.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced the U.S.-South Africa Program for Collaborative Biomedical Research – Phase 3, targeting research projects focused on HIV/AIDS and related health issues. This funding opportunity is an initiative to encourage collaboration between U.S. and South African researchers, fostering partnerships for impactful scientific discovery and public health advancements. With an available funding amount of approximately $3.8 million aimed at supporting 8-10 awards, the program emphasizes the involvement of historically disadvantaged institutions and underrepresented researchers. Eligible applicants must comprise at least one principal investigator from a recognized South African institution collaborating with a U.S. entity. The application must meet specific guidelines, including a significant budget allocation for the South African component. The program outlines comprehensive research objectives, including prevention strategies, treatment advancements, and an emphasis on data science in HIV/AIDS research. Applications are due by March 12, 2025, with the program's overarching goal to enhance research capacity and improve health outcomes for populations affected by HIV/AIDS, specifically targeting diverse and under-resourced groups.
    Similar Opportunities
    Systems Strengthening for Better HIV/TB Patient Outcomes
    Active
    South Africa USAID-Pretoria
    The South Africa USAID-Pretoria is offering a federal grant opportunity titled "Systems Strengthening for Better HIV/TB Patient Outcomes," aimed at enhancing South African Government systems to improve patient outcomes and prevent HIV through comprehensive clinic-based services. Eligible applicants include local South African non-governmental organizations (NGOs) and for-profit organizations that meet specific criteria, with a focus on addressing all three objectives outlined in the Request for Application (RFA) for optimal evaluation. The program has an estimated total funding of $425 million, with individual awards ranging from $10 million to $150 million, and is expected to result in approximately eight awards. Interested organizations should submit their concept papers and full applications as per the guidelines provided, with inquiries directed to Beatrice Lumande at Applications4@usaid.gov or by phone at +27 12 452 2377.
    HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research initiatives focused on HIV-associated non-communicable diseases (NCDs) at low- and middle-income country (LMIC) institutions through the R21 Clinical Trial Optional grant. This program aims to support locally relevant research that explores the relationship between HIV infection and the development of NCDs, enhance research capacity, and foster collaborative networks among researchers in LMICs and the U.S. The grant provides funding up to $275,000 over a two-year period, with a submission deadline of December 8, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
    Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities (R01 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities." This initiative aims to support research that investigates the underlying mechanisms contributing to health disparities in HIV and aging, particularly focusing on how multiple comorbidities affect health outcomes and quality of life among individuals from marginalized populations. The program emphasizes a multidisciplinary approach and encourages engagement with community stakeholders to enhance the relevance of the research. Approximately $3 million is available for four awards and $1.5 million for two additional awards for fiscal year 2024, with a project duration of up to five years. Interested applicants can find more information and guidelines at the NIH Grants website and should direct inquiries to grantsinfo@nih.gov. The application deadline is set for January 7, 2026.
    Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS)," aimed at supporting multidisciplinary research teams investigating HIV pathogenesis and its associated comorbidities. The initiative seeks to foster collaboration among experts in HIV science, pathobiology, metabolism, and related fields to explore critical health issues such as gastrointestinal health, liver diseases, kidney function, and obesity in the context of HIV. With a total funding allocation of $2 million for 2-3 anticipated awards, applicants can request up to $500,000 per year for a maximum of five years, with proposals due by November 21, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research in integrated care models for HIV/AIDS and substance use disorders. The initiative seeks to improve health outcomes and enhance care coordination for individuals at heightened risk by addressing service delivery gaps through collaborative and evidence-based practices. This grant, with a funding ceiling of $450,000 over three years, is open to a diverse range of eligible applicants, including higher education institutions and community-based organizations, with applications due by March 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-020.html.
    Comprehensive District-Based Support for Better HIV/TB Patient Outcomes
    Active
    South Africa USAID-Pretoria
    The United States Agency for International Development (USAID) Mission to Southern Africa is seeking applications for a five-year cooperative agreement aimed at implementing comprehensive district-based HIV-related services to improve patient outcomes. This initiative is part of a broader effort to enhance health services in the region, specifically targeting better management and support for HIV and tuberculosis patients. With an estimated total program funding of $75 million, the agency anticipates awarding four grants, with individual awards ranging from $1 to $20 million. Interested organizations are encouraged to participate in a pre-application conference scheduled for May 14, 2012, in Johannesburg, South Africa, to clarify the application process and technical objectives; registration is required by January 23, 2012. For further inquiries, applicants can contact Beatrice Lumande at Applications4@usaid.gov or by phone at +27 12 452 2377.